Related Articles
Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non‑small cell lung cancers
Absolute lymphocyte count and C‑reactive protein‑albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy
Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer
Neutrophil‑to‑lymphocyte ratio before each chemotherapy line predicts clinical outcomes in patients with unresectable gastric cancer
Prognostic value of the pretreatment neutrophil‑to‑lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure